Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group
- H. M. Colhoun
- … show all 1 hide
The aim of the present study was to examine whether patients with diabetes in Scotland using insulin glargine have a greater cancer risk than patients using other types of insulin.
We used a nationwide diabetes clinical database that covers the majority of the Scottish population with diagnosed diabetes, and examined patients with diabetes who were exposed to any insulin therapy between 1 January 2002 and 31 December 2005. Among these we defined a fixed cohort based on exposure during a 4 month period in 2003 (n = 36,254, in whom 715 cases of cancer occurred) and a cohort of new insulin users across the period (n = 12,852 in whom 381 cancers occurred). Records from these cohorts were linked to cancer registry data up to the end of 2005. We used Cox proportional hazards models for survival analyses.
Those receiving any insulin glargine (n = 3,959) had the same incidence rate for all cancers as those not receiving insulin glargine (HR 1.02, 95% CI 0.77–1.36, p = 0.9 in the fixed cohort) The subset of patients using insulin glargine alone (n = 447) had a significantly higher incidence of all cancers than those using other insulins only (n = 32,295) (HR 1.55, 95% CI 1.01–2.37, p = 0.045), and those using insulin glargine with other insulins (n = 3,512) had a slightly lower incidence (HR 0.81, 95% CI 0.55–1.18, p = 0.26). There were important differences in baseline characteristics between these three groups, although the risk ratios were broadly unaltered on adjustment for these. Overall, there was no increase in breast cancer rates associated with insulin glargine use (HR 1.49, 95% CI 0.79–2.83, though insulin glargine only users had a higher rate than those using non-glargine insulin only (HR 3.39, 95% CI 1.46–7.85, p = 0.004). Among type 2 diabetic incident insulin users, no significant difference between the three groups was observed with respect to all cancer or breast cancer. All the above HRs are adjusted for age, calendar time prior cancer and type of diabetes, as appropriate, and are stratified according to sex.
Overall, insulin glargine use was not associated with an increased risk of all cancers or site-specific cancers in Scotland over a 4 year time frame. Given the overall data, we consider the excess of cases of all cancers and breast cancer in the subgroup of insulin glargine only users to more likely reflect allocation bias rather than an effect of insulin glargine itself.
- sanofi-aventis (2007) LANTUS (insulin glargine [rDNA origin] injection). Available from http://products.sanofi-aventis.us/lantus/lantus.pdf, accessed 15 May 2009
- Lawson DH (2002). Insulin glargine (Lantus): Summary of recommendation. Available from www.scottishmedicines.org.uk/smc/files/Insuline%20Glargine%20FINAL.pdf, accessed 15 May 2009
- National Institute for Clinical Excellence (2002) Guidance on the use of long-acting insulin analogues for the treatment of diabetes insulin glargine. Available from www.nice.org.uk/nicemedia/pdf/53_Insulin_analogues_full_guidance.pdf, accessed 15 May 2009
- National Collaborating Centre for Chronic Conditions (2008) Type 2 diabetes: national clinical guideline for management in primary and secondary care (update). Available from www.nice.org.uk/nicemedia/pdf/CG66diabetesfullguideline.pdf, accessed 15 May 2009
- National Institute for Health and Clinical Excellence (2009) NICE implementation uptake report: insulin glargine for diabetes (types 1 and 2). Available from www.nice.org.uk/media/7B3/7C/IMPUptakeReportTA53CG66GlarginevFinal.pdf, accessed 15 May 2009
- Horvath K, Jeitler K, Berghold A, et al. (2007) Long-acting insulin analogues vs NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev: CD005613
- Singh SR, Ahmad F, Lal A, Yu C, Bai Z, Bennett H (2009) Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. CMAJ 180:385–397
- Hemkens LG, Grouven U, Bender R, Günster C, Gutschmidt S, Selke GW, Sawicki PT (2009) Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia. doi:10.1007/s00125-009-1418-4
- McKnight JA, Morris AD, Cline D, Peden N, Fischbacher C, Wild S (2008) Implementing a national quality assurance system for diabetes care: the Scottish Diabetes Survey 2001–2006. Diabet Med 25:743–746 CrossRef
- Scottish Index of Multiple Deprivation. Available from www.scotland.gov.uk/Topics/Statistics/SIMD/, accessed 20 May 2009
- Brewster DH, Stockton DL (2008) Ascertainment of breast cancer by the Scottish Cancer Registry: an assessment based on comparison with five independent breast cancer trials databases. Breast 17:104–106 CrossRef
- Malignant neoplasms of breast. Available from www.isdscotland.org/isd/5114.html, accessed 20 May 2009
- The Scottish Record Linkage System. Available from http://www.isdscotland.org/isd/files/The%20Scottish%20Record%20Linkage%20System.doc, accessed 23 May 2009
- Rubino A, McQuay LJ, Gough SC, Kvasz M, Tennis P (2007) Delayed initiation of subcutaneous insulin therapy after failure of oral glucose-lowering agents in patients with Type 2 diabetes: a population-based analysis in the UK. Diabet Med 24:1412–1418 CrossRef
- Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD (2005) Metformin and reduced risk of cancer in diabetic patients. BMJ 330:1304–1305 CrossRef
- Stammberger I, Bube A, Durchfeld-Meyer B, Donaubauer H, Troschau G (2002) Evaluation of the carcinogenic potential of insulin glargine (LANTUS) in rats and mice. Int J Toxicol 21:171–179 CrossRef
- Kurtzhals P, Schaffer L, Sorensen A et al (2000) Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49:999–1005 CrossRef
- Erbel S, Reers C, Eckstein VW et al (2008) Proliferation of colo-357 pancreatic carcinoma cells and survival of patients with pancreatic carcinoma are not altered by insulin glargine. Diabetes Care 31:1105–1111 CrossRef
- Mayer D, Shukla A, Enzmann H (2008) Proliferative effects of insulin analogues on mammary epithelial cells. Arch Physiol Biochem 114:38–44 CrossRef
- Weinstein D, Simon M, Yehezkel E, Laron Z, Werner H (2009) Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells. Diabetes Metab Res Rev 25:41–49 CrossRef
- Liefvendahl E, Arnqvist HJ (2008) Mitogenic effect of the insulin analogue glargine in malignant cells in comparison with insulin and IGF-I. Horm Metab Res 40:369–374 CrossRef
- Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
Volume 52, Issue 9 , pp 1755-1765
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Industry Sectors
- H. M. Colhoun (1)
- Author Affiliations
- 1. Biomedical Research Institute, University of Dundee, Mackenzie Building, Kirsty Semple Way, Dundee, DD2 4BF, Scotland, UK